Access expired on Sunday, November 15, 2020
This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.
Already Have An Account? Log in Now
story of the week
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
J. Clin. Oncol 2020 Oct 06;[EPub Ahead of Print], MA Dimopoulos, I Špička, H Quach, A Oriol, R Hájek, M Garg, M Beksac, S Bringhen, E Katodritou, WJ Chng, X Leleu, S Iida, MV Mateos, G Morgan, A Vorog, R Labotka, B Wang, A Palumbo, S LonialFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.